2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
124
Multiple Myeloma
84
Precursor Cell Lymphoblastic Leukemia-Lymphoma
76
Lymphoma
73
Lymphoma, Non-Hodgkin
66
Leukemia
66
Myelodysplastic Syndromes
56
Hodgkin Disease
53
Lymphoma, Large B-Cell, Diffuse
37
Lymphoma, Mantle-Cell
33
Breast Neoplasms
32
Neuroblastoma
30
Leukemia, Lymphocytic, Chronic, B-Cell
30
Burkitt Lymphoma
30
Lymphoma, Follicular
26
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
26
Recurrence
24
Sarcoma
18
Neoplasms, Plasma Cell
18
Hematologic Neoplasms
18
Central Nervous System Neoplasms
18
Lymphoma, B-Cell, Marginal Zone
17
Leukemia, Biphenotypic, Acute
16
Myeloproliferative Disorders
15
Lymphoma, Large-Cell, Immunoblastic
15
Congenital Abnormalities
15
Brain Neoplasms
14
Leukemia, Myelomonocytic, Chronic
13
Anemia, Refractory, with Excess of Blasts
13
Medulloblastoma
12
Interventions
Specimen Handling
1
Imatinib Mesylate
1
Granulocyte Colony-Stimulating Factor
1
Genetic Counseling
1
Filgrastim
1
Decitabine
1
Clinical Trials, Phase I as Topic
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Congenital Bone Marrow Failure Syndromes
×
Granulocyte Colony-Stimulating Factor
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled